Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$18.00
0.905.26%
At close: -
$18.00
0.000.00%
After Hours: Jun 27, 4:29 PM EDT
Comments
Loading...
NovoCure Analyst Ratings and Price Targets | NASDAQ:NVCR | Benzinga
NovoCure Ltd has a consensus price target of $48.67 based on the ratings of 9 analysts. The high is $95 issued by Truist Securities on June 6, 2023. The low is $27 issued by Wedbush on April 16, 2025. The 3 most-recent analyst ratings were released by Piper Sandler, Piper Sandler, and Wedbush on June 27, 2025, April 23, 2025, and April 16, 2025, respectively. With an average price target of $31.67 between Piper Sandler, Piper Sandler, and Wedbush, there's an implied 75.93% upside for NovoCure Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Piper Sandler
Wedbush
JP Morgan
HC Wainwright & Co.
Evercore ISI Group
1calculated from analyst ratings
Analyst Ratings for NovoCure
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/27/2025 | Buy Now | 88.89% | Piper Sandler | Jason Bednar53% | $34 → $34 | Reiterates | Overweight → Overweight | Get Alert |
| 04/23/2025 | Buy Now | 88.89% | Piper Sandler | Jason Bednar53% | $42 → $34 | Maintains | Overweight | Get Alert |
| 04/16/2025 | Buy Now | 50% | Wedbush | David Nierengarten61% | $29 → $27 | Maintains | Neutral | Get Alert |
| 04/10/2025 | Buy Now | 55.56% | JP Morgan | Jessica Fye67% | $29 → $28 | Maintains | Neutral | Get Alert |
| 01/14/2025 | Buy Now | 111.11% | HC Wainwright & Co. | Emily Bodnar39% | $38 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 133.33% | Piper Sandler | Jason Bednar53% | $28 → $42 | Maintains | Overweight | Get Alert |
| 12/03/2024 | Buy Now | 111.11% | HC Wainwright & Co. | Emily Bodnar39% | $30 → $38 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 111.11% | HC Wainwright & Co. | Emily Bodnar39% | $30 → $38 | Reiterates | Buy → Buy | Get Alert |
| 12/02/2024 | Buy Now | 66.67% | Evercore ISI Group | Vijay Kumar50% | $18 → $30 | Upgrade | In-Line → Outperform | Get Alert |
| 11/21/2024 | Buy Now | 66.67% | HC Wainwright & Co. | Emily Bodnar39% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 66.67% | HC Wainwright & Co. | Emily Bodnar39% | $30 → $30 | Reiterates | Buy → Buy | Get Alert |
| 10/16/2024 | Buy Now | 66.67% | HC Wainwright & Co. | Emily Bodnar39% | $24 → $30 | Upgrade | Neutral → Buy | Get Alert |
| 10/01/2024 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | $21 → $18 | Maintains | In-Line | Get Alert |
| 07/26/2024 | Buy Now | 122.22% | Wells Fargo | Larry Biegelsen65% | $42 → $40 | Maintains | Overweight | Get Alert |
| 07/26/2024 | Buy Now | 33.33% | HC Wainwright & Co. | Emily Bodnar39% | $22 → $24 | Maintains | Neutral | Get Alert |
| 07/02/2024 | Buy Now | 11.11% | Evercore ISI Group | Vijay Kumar50% | $14.5 → $20 | Maintains | In-Line | Get Alert |
| 06/04/2024 | Buy Now | 22.22% | HC Wainwright & Co. | Emily Bodnar39% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 05/02/2024 | Buy Now | 22.22% | HC Wainwright & Co. | Emily Bodnar39% | $24 → $22 | Maintains | Neutral | Get Alert |
| 04/10/2024 | Buy Now | 55.56% | Piper Sandler | Jason Bednar53% | $25 → $28 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 133.33% | Wells Fargo | Larry Biegelsen65% | $49 → $42 | Maintains | Overweight | Get Alert |
| 03/27/2024 | Buy Now | 33.33% | HC Wainwright & Co. | Emily Bodnar39% | $22 → $24 | Maintains | Neutral | Get Alert |
| 03/19/2024 | Buy Now | -5.56% | JP Morgan | Jessica Fye67% | $15 → $17 | Maintains | Neutral | Get Alert |
| 03/12/2024 | Buy Now | 22.22% | HC Wainwright & Co. | Emily Bodnar39% | $22 → $22 | Reiterates | Neutral → Neutral | Get Alert |
| 02/23/2024 | Buy Now | -16.67% | Evercore ISI Group | Vijay Kumar50% | $14 → $15 | Maintains | In-Line | Get Alert |
| 02/22/2024 | Buy Now | 22.22% | HC Wainwright & Co. | Emily Bodnar39% | $21 → $22 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | 172.22% | Wells Fargo | Larry Biegelsen65% | $102 → $49 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | 38.89% | HC Wainwright & Co. | Emily Bodnar39% | → $25 | Downgrade | Buy → Neutral | Get Alert |
| 08/08/2023 | Buy Now | 150% | Piper Sandler | Jason Bednar53% | → $45 | Upgrade | Neutral → Overweight | Get Alert |
| 08/04/2023 | Buy Now | 183.33% | SVB Leerink | Jonathan Chang38% | → $51 | Initiates | → Outperform | Get Alert |
| 07/31/2023 | Buy Now | 83.33% | Evercore ISI Group | Vijay Kumar50% | → $33 | Upgrade | Underperform → In-Line | Get Alert |
| 07/28/2023 | Buy Now | 466.67% | Wells Fargo | Larry Biegelsen65% | $104 → $102 | Maintains | Overweight | Get Alert |
| 07/27/2023 | Buy Now | 372.22% | HC Wainwright & Co. | Emily Bodnar39% | → $85 | Reiterates | Buy → Buy | Get Alert |
| 06/07/2023 | Buy Now | 244.44% | Piper Sandler | Jason Bednar53% | $67 → $62 | Maintains | Neutral | Get Alert |
| 06/07/2023 | Buy Now | 155.56% | Wedbush | David Nierengarten61% | $53 → $46 | Upgrade | Underperform → Neutral | Get Alert |
| 06/06/2023 | Buy Now | 427.78% | Truist Securities | Gregory Fraser63% | → $95 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2023 | Buy Now | 538.89% | HC Wainwright & Co. | Emily Bodnar39% | → $115 | Reiterates | Buy → Buy | Get Alert |
| 05/16/2023 | Buy Now | 477.78% | Wells Fargo | Larry Biegelsen65% | $70 → $104 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 05/05/2023 | Buy Now | 427.78% | Truist Securities | Gregory Lewis72% | $102 → $95 | Maintains | Buy | Get Alert |
| 05/04/2023 | Buy Now | 538.89% | HC Wainwright & Co. | Emily Bodnar39% | $130 → $115 | Maintains | Buy | Get Alert |
| 03/17/2023 | Buy Now | 177.78% | JP Morgan | Jessica Fye67% | $99 → $50 | Downgrade | Neutral → Underweight | Get Alert |
| 01/17/2023 | Buy Now | 344.44% | Piper Sandler | Jason Bednar53% | $70 → $80 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 450% | JP Morgan | Jessica Fye67% | $86 → $99 | Maintains | Neutral | Get Alert |
| 01/06/2023 | Buy Now | 494.44% | Wells Fargo | Larry Biegelsen65% | $89 → $107 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/29/2022 | Buy Now | 394.44% | Wells Fargo | Larry Biegelsen65% | $74 → $89 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 10/28/2022 | Buy Now | 466.67% | Truist Securities | Gregory Fraser63% | $105 → $102 | Maintains | Buy | Get Alert |
| 10/28/2022 | Buy Now | 311.11% | Wells Fargo | Larry Biegelsen65% | $70 → $74 | Maintains | Equal-Weight | Get Alert |
| 10/28/2022 | Buy Now | 455.56% | HC Wainwright & Co. | Emily Bodnar39% | $115 → $100 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | 288.89% | Piper Sandler | Jason Bednar53% | $90 → $70 | Downgrade | Overweight → Neutral | Get Alert |
| 07/29/2022 | Buy Now | 483.33% | Truist Securities | Gregory Fraser63% | $118 → $105 | Maintains | Buy | Get Alert |
| 07/05/2022 | Buy Now | — | Evercore ISI Group | Vijay Kumar50% | — | Downgrade | In-Line → Underperform | Get Alert |
FAQ
What is the target price for NovoCure (NVCR) stock?
The latest price target for NovoCure (NASDAQ:NVCR) was reported by Piper Sandler on June 27, 2025. The analyst firm set a price target for $34.00 expecting NVCR to rise to within 12 months (a possible 88.89% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NovoCure (NVCR)?
The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by Piper Sandler, and NovoCure reiterated their overweight rating.
When was the last upgrade for NovoCure (NVCR)?
The last upgrade for NovoCure Ltd happened on December 2, 2024 when Evercore ISI Group raised their price target to $30. Evercore ISI Group previously had an in-line for NovoCure Ltd.
When was the last downgrade for NovoCure (NVCR)?
The last downgrade for NovoCure Ltd happened on August 28, 2023 when HC Wainwright & Co. changed their price target from N/A to $25 for NovoCure Ltd.
When is the next analyst rating going to be posted or updated for NovoCure (NVCR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.
Is the Analyst Rating NovoCure (NVCR) correct?
While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a reiterated with a price target of $34.00 to $34.00. The current price NovoCure (NVCR) is trading at is $18.00, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
